Puma Biotechnology
PBYI
9.60
-0.22
-2.19%
Puma Biotechnology
US · PBYI
#3745 by market cap
9.60
-0.22
-2.19%
Live - 5344 symbols - heartbeat 275s ago
· 2026-10-08 09:58
Pre-market
9.68
-1.33%
After-hours
9.81
0.00%
- Market cap
- 495.29M
- P/E (TTM)i
- 18.81
- P/Bi
- 3.57
- EPSi
- 0.61
- Div yieldi
- 0.00%
- 52W posi
- 91%
Reader sentiment
Are you bullish or bearish on PBYI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -2.78, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -0.91% YoY
Margins
- Gross margin
- 74.53%
- Operating margin
- 16.33%
- Net margin
- 13.62%
Key ratios & quality
- PEG ratioi
- 0.01
- Altman Z-Scorei
- -2.78
PEG uses trailing P/E against the 3-year net income growth rate (2,396.29%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 250.99M | 272.26M | 225.11M | 253.16M | 228.03M | 235.64M | 230.47M | 228.37M |
| Gross profit | 216.37M | 235.45M | 185.74M | 189.45M | 172.94M | 172.96M | 166.06M | 170.21M |
| Selling & admin expenses | 146.17M | 141.64M | 118.49M | 116.29M | 89.98M | 89.93M | 80.68M | 71.21M |
| Research & development | 164.85M | 132.85M | 97.65M | 71.87M | 52.24M | 50.38M | 54.94M | 62.07M |
| Operating profit | -94.66M | -39.05M | -30.40M | 1.29M | 30.72M | 32.64M | 30.97M | 37.30M |
| Pretax profit | -113.56M | -75.54M | -59.79M | -28.80M | 457.00K | 22.67M | 24.10M | 35.78M |
| Tax | 17.00K | 53.00K | 207.00K | 324.00K | 455.00K | 1.08M | -6.18M | 4.67M |
| Net profit | -113.58M | -75.60M | -60.00M | -29.13M | 2.00K | 21.59M | 30.28M | 31.11M |
| Basic EPS | -3 | -2 | -2 | -1 | 0 | 0 | 1 | 1 |
| Diluted EPS | -2.99 | -1.95 | -1.52 | -0.72 | 0.00 | 0.45 | 0.62 | 0.61 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 46.01M | 52.44M | 54.48M | 75.45M | 44.81M | 56.50M |
| Gross profit | 35.45M | 40.14M | 42.30M | 52.33M | 34.39M | 44.03M |
| Selling & admin expenses | 17.39M | 18.41M | 17.03M | 18.38M | 18.42M | 17.55M |
| Research & development | 13.86M | 15.45M | 15.91M | 16.84M | 19.80M | 18.90M |
| Operating profit | 3.98M | 6.64M | 9.57M | 17.11M | -3.83M | 7.59M |
| Pretax profit | 3.27M | 6.17M | 9.24M | 17.11M | -3.43M | 8.25M |
| Tax | 293.00K | 310.00K | 399.00K | 3.67M | 326.00K | 56.00K |
| Net profit | 2.97M | 5.86M | 8.84M | 13.44M | -3.75M | 8.19M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.06 | 0.12 | 0.17 | 0.26 | -0.07 | 0.16 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 203.00M | 166.30M | 146.14M | 140.02M | 134.28M | 156.19M | 147.66M | 162.69M |
| Cash & ST investments | 165.42M | 111.64M | 93.39M | 82.11M | 81.07M | 95.94M | 100.97M | 97.53M |
| Inventory | 2.63M | 3.17M | 3.45M | 7.11M | 4.53M | 7.08M | 8.72M | 5.52M |
| Total assets | 259.12M | 234.91M | 244.22M | 226.59M | 222.06M | 230.53M | 213.33M | 216.30M |
| Total current liabilities | 67.12M | 90.84M | 114.26M | 109.59M | 77.48M | 99.38M | 96.11M | 81.25M |
| Short-term debt | -- | 2.62M | 17.38M | 3.57M | 4.14M | 38.80M | 50.87M | 23.84M |
| Long-term debt | 151.89M | 94.96M | 84.03M | 97.09M | 98.31M | 65.66M | 21.72M | -- |
| Total liabilities | 224,816,000.00 | 217,442,000.00 | 250,171,000.00 | 229,031,000.00 | 200,451,000.00 | 177,086,000.00 | 121,208,000.00 | 85,962,000.00 |
| Total equity | 34.31M | 17.46M | -5.95M | -2.45M | 21.61M | 53.44M | 92.13M | 130.34M |
| Retained earnings | -1.20B | -1.28B | -1.34B | -1.37B | -1.37B | -1.35B | -1.31B | -1.28B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 132.51M | 136.58M | 143.58M | 162.69M | 142.26M | 145.07M |
| Cash & ST investments | 93.17M | 96.02M | 94.39M | 97.53M | 101.55M | 93.90M |
| Inventory | 8.75M | 8.59M | 9.48M | 5.52M | 8.69M | 13.32M |
| Total assets | 196.18M | 194.92M | 202.86M | 216.30M | 192.70M | 192.74M |
| Total current liabilities | 86.66M | 79.10M | 82.73M | 81.25M | 59.74M | 49.83M |
| Short-term debt | 51.07M | 38.36M | 36.19M | 23.84M | 11.41M | 450.00K |
| Long-term debt | 10.65M | 10.87M | -- | -- | -- | -- |
| Total liabilities | 99,073,000.00 | 90,198,000.00 | 87,594,000.00 | 85,962,000.00 | 64,283,000.00 | 54,192,000.00 |
| Total equity | 97.11M | 104.72M | 115.27M | 130.34M | 128.42M | 138.54M |
| Retained earnings | -1.31B | -1.31B | -1.30B | -1.28B | -1.29B | -1.28B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -24.11M | 22.38M | 773.00K | 20.65M | -15.83M | 27.01M | 38.92M | 41.80M |
| Depreciation & amortization | 7.38M | 8.08M | 10.03M | 11.31M | 9.84M | 11.52M | 11.52M | 10.94M |
| Free cash flow | -24.71M | 22.07M | -9.27M | 20.65M | -22.83M | 14.37M | 38.86M | 41.73M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | 12.50M | -- | -- | -- |
| Ending cash balance | 112.74M | 73.21M | 97.45M | 75.29M | 78.79M | 86.68M | 71.31M | 31.73M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 3.61M | 14.08M | 9.69M | 14.42M | 15.42M | 1.62M |
| Depreciation & amortization | 2.80M | 2.76M | 2.72M | 2.66M | 2.58M | 2.52M |
| Free cash flow | 3.55M | 14.06M | 9.66M | 14.46M | 15.42M | 1.62M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 65.12M | 56.75M | 55.62M | 31.73M | 38.28M | 36.54M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -259.28 | -292.05 | -1,042.30 | -- | 0.02 | 57.54 | 41.60 | 27.97 |
| ROA %i | -53.49 | -30.60 | -25.04 | -12.37 | 0.00 | 9.54 | 13.64 | 14.48 |
| ROIC %i | -72.50 | -38.85 | -39.65 | -- | 6.81 | 21.14 | 21.97 | 20.50 |
| 5-year avg ROE %i | -180.66 | -210.83 | -389.66 | -- | -- | -- | -- | -- |
| EBIT margin %i | -40.87 | -22.25 | -20.32 | -6.32 | 5.28 | 15.28 | 15.86 | 18.57 |
| FCF / sales %i | -- | 8.11 | -- | 8.16 | -- | 6.10 | 16.86 | 18.27 |
| Current ratioi | 3.02 | 1.83 | 1.28 | 1.28 | 1.73 | 1.57 | 1.54 | 2.00 |
| Quick ratioi | 2.79 | 1.55 | 1.04 | 1.05 | 1.59 | 1.45 | 1.38 | 1.86 |
| Debt / assetsi | 58.62 | 51.18 | 49.53 | 51.48 | 51.46 | 48.36 | 34.73 | 13.20 |
| LT debt / equityi | 442.74 | 673.45 | -- | -- | 509.72 | 136.02 | 25.20 | 3.61 |
| Interest coveragei | -9.34 | -4.03 | -3.26 | -1.25 | 1.04 | 2.70 | 2.94 | 6.40 |
| Revenue CAGR (3Y) %i | -- | -- | 101.09 | 0.29 | -5.74 | 1.54 | -3.08 | 0.05 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | 2,396.29 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 23.46 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 51.41 | 63.24 | 39.69 | 27.97 | 21.62 | 21.97 |
| ROA %i | 18.55 | 24.23 | 17.46 | 14.48 | 12.54 | 13.78 |
| ROIC %i | 26.91 | 34.90 | 25.48 | 20.50 | 16.75 | 17.78 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 18.58 | 21.85 | 18.41 | 18.57 | 15.08 | 15.00 |
| FCF / sales %i | 13.39 | 18.58 | 20.22 | 18.27 | 23.59 | 17.80 |
| Current ratioi | 1.53 | 1.73 | 1.74 | 2.00 | 2.38 | 2.91 |
| Quick ratioi | 1.37 | 1.54 | 1.55 | 1.86 | 2.14 | 2.57 |
| Debt / assetsi | 31.46 | 25.26 | 20.24 | 13.20 | 8.28 | 2.50 |
| LT debt / equityi | 10.96 | 10.38 | 4.22 | 3.61 | 3.54 | 3.15 |
| Interest coveragei | 3.84 | 5.34 | 4.81 | 6.40 | 6.62 | 9.86 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development and commercialization of innovative products to enhance cancer care100.00%
Quote time 2026-10-08 09:58:52 · For reference only, not investment advice and not tailored to your situation.